What is PGEN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.84B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PGEN?

P/E (TTM) is n/a and 52-week range is $3.04 to $8.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PGEN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PGEN?

The company profile lists revenue (TTM) near $74M, net income (TTM) near -$13.65B, EPS (TTM) near -$0.52 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Precigen, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Germantown, Maryland, US, 358M shares outstanding, ISIN US74017N1054 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Precigen, Inc.

$PGEN

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Employees

160

Website

precigen.com/

IPO

2013-08-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US74017N1054

Headquarters

Germantown, Maryland, US

Shares outstanding

358M

NAICS sector

Manufacturing

Institutional ownership

72.38%

Browse other companiesFree AI scores and summaries for more stocks